The biological properties of cetuximab
- 1 November 2008
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 68 (2) , 93-106
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2008
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBritish Journal of Cancer, 2007
- When EGF is offside, magnesium is wastedJournal of Clinical Investigation, 2007
- Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemiaJournal of Clinical Investigation, 2007
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 2007
- Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor BiologyJournal of Clinical Oncology, 2005
- Restoring Apoptosis in Pancreatic Cancer Cells by Targeting the Nuclear Factor-κB Signaling Pathway With the Anti-Epidermal Growth Factor Antibody IMC-C225Journal of Gastrointestinal Surgery, 2003
- Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibodyOncogene, 2001
- Increased epidermal growth factor receptor in multidrug‐resistant human neuroblastoma cellsJournal of Cellular Biochemistry, 1988